SAGE THERAPEUTICS INC's ticker is SAGE and the CUSIP is 78667J108. A total of 270 filers reported holding SAGE THERAPEUTICS INC in Q4 2019. The put-call ratio across all filers is 0.78 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2023 | $794 | -48.9% | 16,892 | -54.4% | 0.01% | -63.2% |
| Q1 2023 | $1,555 | +98.6% | 37,072 | +80.4% | 0.02% | +72.7% |
| Q4 2022 | $783 | -99.9% | 20,550 | +50.4% | 0.01% | +83.3% |
| Q3 2022 | $535,000 | -16.3% | 13,665 | -29.3% | 0.01% | +20.0% |
| Q1 2022 | $639,000 | -38.9% | 19,319 | -21.4% | 0.01% | -16.7% |
| Q4 2021 | $1,045,000 | -6.9% | 24,574 | -3.0% | 0.01% | -14.3% |
| Q3 2021 | $1,123,000 | +41.1% | 25,346 | +138.2% | 0.01% | -12.5% |
| Q1 2021 | $796,000 | +20.4% | 10,640 | +39.0% | 0.01% | -38.5% |
| Q4 2020 | $661,000 | -62.4% | 7,652 | -73.4% | 0.01% | -74.5% |
| Q3 2020 | $1,758,000 | +173.0% | 28,765 | +85.5% | 0.05% | +168.4% |
| Q2 2020 | $644,000 | +106.4% | 15,503 | +595.8% | 0.02% | +26.7% |
| Q3 2019 | $312,000 | -37.6% | 2,228 | -30.4% | 0.02% | -91.8% |
| Q2 2018 | $500,000 | – | 3,200 | – | 0.18% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Finepoint Capital LP | 475,600 | $15,362,000 | 5.31% |
| Integral Health Asset Management, LLC | 412,257 | $13,316,000 | 2.74% |
| Palo Alto Investors LP | 851,409 | $27,501,000 | 2.40% |
| Boxer Capital, LLC | 1,094,000 | $35,336,000 | 2.24% |
| DAFNA Capital Management LLC | 180,306 | $5,824,000 | 1.59% |
| Ikarian Capital, LLC | 250,000 | $8,075,000 | 1.47% |
| Bellevue Group AG | 2,973,178 | $96,034,000 | 1.36% |
| SECTOR GAMMA AS | 118,476 | $3,827,000 | 0.86% |
| Artal Group S.A. | 450,000 | $14,535,000 | 0.78% |
| Diametric Capital, LP | 19,393 | $626,000 | 0.46% |